PARIS (Reuters) – An experimental anti-clotting drug from Bristol-Myers Squibb and Pfizer saved more lives than standard treatment warfarin in a major study, giving it an edge over rivals in an emerging multibillion-dollar market. Although Eliquis will be third to market among a wave of new oral anticoagulants, the data…
By Ana Marie Cox, The Guardian
Read More
By Amanda Marcotte
Read More
By Amanda Marcotte
Read More
Raw Story is a progressive news site that focuses on stories often ignored in the mainstream media. While giving coverage to the big stories of the day, we also bring our readers' attention to policy, politics, legal and human rights stories that get ignored in an infotainment culture driven solely by pageviews.
Founded in 2004, Raw Story reaches 5 million unique readers per month and serves more than 19 million pageviews.
Copyright © 2004-2013 Raw Story Media, Inc. All rights reserved.